Gastroparesis Drugs for Medical Implants Market 2027 By Drug Class, Disease Type, End User and Geography | The Insight Partners

Gastroparesis Drugs for Medical Implants Market to 2027 - Global Analysis and Forecasts By Drug Class (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injections); Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, Others); End User (Hospitals, Pharmacies, Clinics, E-commerce) and Geography

Report Code: TIPRE00004764 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Gastroparesis is a condition that occurs due to inappropriate working of digestive system and leads to improper functioning of the stomach. Gastroparesis is caused due to diabetes, medications such as antidepressants, injuries to the vagus nerve that controls the digestive system and others. This condition can lead to the growth of bacteria in stomach. The Gastroparesis is a chronic disease that lasts for long duration and have no commercially available treatment options for its cure.

MARKET DYNAMICS
The global gastroparesis drugs market is expected to grow due to increase in geriatric population, rise in number of surgeries leading to gastroparesis, increase in usage of drugs for vomiting and nausea, increase in the prevalence of diabetes and others. On the other hand, increase in funding for improving healthcare infrastructure, and emergence of new local players within the developing economies are expected to provide opportunities in market growth.

MARKET SCOPE
The "Global Gastroparesis Drugs Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of gastroparesis drugs market with detailed market segmentation by drug class, disease type, end user and geography. The global gastroparesis drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading gastroparesis drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global gastroparesis drugs market is segmented on the basis of drug class, disease type, and end user Based on drug class, the market is segmented as prokinetic agents, antiemetic agents, and botulinum toxin injections. Based on disease type the market is segmented as diabetic gastroparesis, idiopathic gastroparesis, post-surgical gastroparesis, others. On the basis of end user the gastroparesis drugs market is segmented into hospitals, pharmacies, clinics, and e-commerce.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global gastroparesis drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The gastroparesis drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting gastroparesis drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the gastroparesis drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the gastroparesis drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from gastroparesis drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for gastroparesis drugs in the global market. Below mentioned is the list of few companies engaged in the gastroparesis drugs market.

The report also includes the profiles of key gastroparesis drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • ALLERGAN
  • Abbott
  • AstraZeneca Plc.
  • Cadila Pharmaceuticals
  • ETX Pharma, Inc.
  • Evoke Pharma
  • GlaxoSmithKline Plc.
  • Neurogastrx, Inc.
  • Bausch Health Companies Inc.
  • Theravance Biopharma
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Gastroparesis Drugs Market - By Drug Class
1.3.2 Gastroparesis Drugs Market - By Disease Type
1.3.3 Gastroparesis Drugs Market - By End User
1.3.4 Gastroparesis Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GASTROPARESIS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GASTROPARESIS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GASTROPARESIS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. GASTROPARESIS DRUGS - GLOBAL MARKET OVERVIEW
6.2. GASTROPARESIS DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. GASTROPARESIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. PROKINETIC AGENTS
7.3.1. Overview
7.3.2. Prokinetic Agents Market Forecast and Analysis
7.4. ANTIEMETIC AGENTS
7.4.1. Overview
7.4.2. Antiemetic Agents Market Forecast and Analysis
7.5. BOTULINUM TOXIN INJECTIONS
7.5.1. Overview
7.5.2. Botulinum Toxin Injections Market Forecast and Analysis
8. GASTROPARESIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
8.1. OVERVIEW
8.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
8.3. DIABETIC GASTROPARESIS
8.3.1. Overview
8.3.2. Diabetic Gastroparesis Market Forecast and Analysis
8.4. IDIOPATHIC GASTROPARESIS
8.4.1. Overview
8.4.2. Idiopathic Gastroparesis Market Forecast and Analysis
8.5. POST-SURGICAL GASTROPARESIS
8.5.1. Overview
8.5.2. Post-surgical Gastroparesis Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. GASTROPARESIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. PHARMACIES
9.4.1. Overview
9.4.2. Pharmacies Market Forecast and Analysis
9.5. CLINICS
9.5.1. Overview
9.5.2. Clinics Market Forecast and Analysis
9.6. E-COMMERCE
9.6.1. Overview
9.6.2. E-commerce Market Forecast and Analysis
10. GASTROPARESIS DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Gastroparesis Drugs Market Overview
10.1.2 North America Gastroparesis Drugs Market Forecasts and Analysis
10.1.3 North America Gastroparesis Drugs Market Forecasts and Analysis - By Drug Class
10.1.4 North America Gastroparesis Drugs Market Forecasts and Analysis - By Disease Type
10.1.5 North America Gastroparesis Drugs Market Forecasts and Analysis - By End User
10.1.6 North America Gastroparesis Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Gastroparesis Drugs Market
10.1.6.1.1 United States Gastroparesis Drugs Market by Drug Class
10.1.6.1.2 United States Gastroparesis Drugs Market by Disease Type
10.1.6.1.3 United States Gastroparesis Drugs Market by End User
10.1.6.2 Canada Gastroparesis Drugs Market
10.1.6.2.1 Canada Gastroparesis Drugs Market by Drug Class
10.1.6.2.2 Canada Gastroparesis Drugs Market by Disease Type
10.1.6.2.3 Canada Gastroparesis Drugs Market by End User
10.1.6.3 Mexico Gastroparesis Drugs Market
10.1.6.3.1 Mexico Gastroparesis Drugs Market by Drug Class
10.1.6.3.2 Mexico Gastroparesis Drugs Market by Disease Type
10.1.6.3.3 Mexico Gastroparesis Drugs Market by End User
10.2. EUROPE
10.2.1 Europe Gastroparesis Drugs Market Overview
10.2.2 Europe Gastroparesis Drugs Market Forecasts and Analysis
10.2.3 Europe Gastroparesis Drugs Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Gastroparesis Drugs Market Forecasts and Analysis - By Disease Type
10.2.5 Europe Gastroparesis Drugs Market Forecasts and Analysis - By End User
10.2.6 Europe Gastroparesis Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Gastroparesis Drugs Market
10.2.6.1.1 Germany Gastroparesis Drugs Market by Drug Class
10.2.6.1.2 Germany Gastroparesis Drugs Market by Disease Type
10.2.6.1.3 Germany Gastroparesis Drugs Market by End User
10.2.6.2 France Gastroparesis Drugs Market
10.2.6.2.1 France Gastroparesis Drugs Market by Drug Class
10.2.6.2.2 France Gastroparesis Drugs Market by Disease Type
10.2.6.2.3 France Gastroparesis Drugs Market by End User
10.2.6.3 Italy Gastroparesis Drugs Market
10.2.6.3.1 Italy Gastroparesis Drugs Market by Drug Class
10.2.6.3.2 Italy Gastroparesis Drugs Market by Disease Type
10.2.6.3.3 Italy Gastroparesis Drugs Market by End User
10.2.6.4 Spain Gastroparesis Drugs Market
10.2.6.4.1 Spain Gastroparesis Drugs Market by Drug Class
10.2.6.4.2 Spain Gastroparesis Drugs Market by Disease Type
10.2.6.4.3 Spain Gastroparesis Drugs Market by End User
10.2.6.5 United Kingdom Gastroparesis Drugs Market
10.2.6.5.1 United Kingdom Gastroparesis Drugs Market by Drug Class
10.2.6.5.2 United Kingdom Gastroparesis Drugs Market by Disease Type
10.2.6.5.3 United Kingdom Gastroparesis Drugs Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Gastroparesis Drugs Market Overview
10.3.2 Asia-Pacific Gastroparesis Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Gastroparesis Drugs Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Gastroparesis Drugs Market Forecasts and Analysis - By Disease Type
10.3.5 Asia-Pacific Gastroparesis Drugs Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Gastroparesis Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Gastroparesis Drugs Market
10.3.6.1.1 Australia Gastroparesis Drugs Market by Drug Class
10.3.6.1.2 Australia Gastroparesis Drugs Market by Disease Type
10.3.6.1.3 Australia Gastroparesis Drugs Market by End User
10.3.6.2 China Gastroparesis Drugs Market
10.3.6.2.1 China Gastroparesis Drugs Market by Drug Class
10.3.6.2.2 China Gastroparesis Drugs Market by Disease Type
10.3.6.2.3 China Gastroparesis Drugs Market by End User
10.3.6.3 India Gastroparesis Drugs Market
10.3.6.3.1 India Gastroparesis Drugs Market by Drug Class
10.3.6.3.2 India Gastroparesis Drugs Market by Disease Type
10.3.6.3.3 India Gastroparesis Drugs Market by End User
10.3.6.4 Japan Gastroparesis Drugs Market
10.3.6.4.1 Japan Gastroparesis Drugs Market by Drug Class
10.3.6.4.2 Japan Gastroparesis Drugs Market by Disease Type
10.3.6.4.3 Japan Gastroparesis Drugs Market by End User
10.3.6.5 South Korea Gastroparesis Drugs Market
10.3.6.5.1 South Korea Gastroparesis Drugs Market by Drug Class
10.3.6.5.2 South Korea Gastroparesis Drugs Market by Disease Type
10.3.6.5.3 South Korea Gastroparesis Drugs Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Gastroparesis Drugs Market Overview
10.4.2 Middle East and Africa Gastroparesis Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Gastroparesis Drugs Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Gastroparesis Drugs Market Forecasts and Analysis - By Disease Type
10.4.5 Middle East and Africa Gastroparesis Drugs Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Gastroparesis Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Gastroparesis Drugs Market
10.4.6.1.1 South Africa Gastroparesis Drugs Market by Drug Class
10.4.6.1.2 South Africa Gastroparesis Drugs Market by Disease Type
10.4.6.1.3 South Africa Gastroparesis Drugs Market by End User
10.4.6.2 Saudi Arabia Gastroparesis Drugs Market
10.4.6.2.1 Saudi Arabia Gastroparesis Drugs Market by Drug Class
10.4.6.2.2 Saudi Arabia Gastroparesis Drugs Market by Disease Type
10.4.6.2.3 Saudi Arabia Gastroparesis Drugs Market by End User
10.4.6.3 U.A.E Gastroparesis Drugs Market
10.4.6.3.1 U.A.E Gastroparesis Drugs Market by Drug Class
10.4.6.3.2 U.A.E Gastroparesis Drugs Market by Disease Type
10.4.6.3.3 U.A.E Gastroparesis Drugs Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Gastroparesis Drugs Market Overview
10.5.2 South and Central America Gastroparesis Drugs Market Forecasts and Analysis
10.5.3 South and Central America Gastroparesis Drugs Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Gastroparesis Drugs Market Forecasts and Analysis - By Disease Type
10.5.5 South and Central America Gastroparesis Drugs Market Forecasts and Analysis - By End User
10.5.6 South and Central America Gastroparesis Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Gastroparesis Drugs Market
10.5.6.1.1 Brazil Gastroparesis Drugs Market by Drug Class
10.5.6.1.2 Brazil Gastroparesis Drugs Market by Disease Type
10.5.6.1.3 Brazil Gastroparesis Drugs Market by End User
10.5.6.2 Argentina Gastroparesis Drugs Market
10.5.6.2.1 Argentina Gastroparesis Drugs Market by Drug Class
10.5.6.2.2 Argentina Gastroparesis Drugs Market by Disease Type
10.5.6.2.3 Argentina Gastroparesis Drugs Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. GASTROPARESIS DRUGS MARKET, KEY COMPANY PROFILES
12.1. ALLERGAN.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ABBOTT.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ASTRAZENECA PLC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CADILA PHARMACEUTICALS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ETX PHARMA, INC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. EVOKE PHARMA
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. GLAXOSMITHKLINE PLC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NEUROGASTRX, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BAUSCH HEALTH COMPANIES INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. THERAVANCE BIOPHARMA.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. ALLERGAN
2. Abbott
3. AstraZeneca Plc.
4. Cadila Pharmaceuticals
5. ETX Pharma, Inc.
6. Evoke Pharma
7. GlaxoSmithKline Plc.
8. Neurogastrx, Inc.
9. Bausch Health Companies Inc.
10. Theravance Biopharma.